GALD Share Price Performance
CHF 0
-123.20 (-100.00%)
Price CHF 0
Fair ValueCHF 131.68
Share Pricen/a
Narrative Update • Jul 16
Galderma Group AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 25 Fair Values set on narratives written by author
GALD Community Narratives
AN
Fair Value
·Fair Value CHF 131.68 32.2% overvalued intrinsic discount
Rising Global Controls And Biosimilar Risks Will Squeeze Margins
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value CHF 188.31 7.6% undervalued intrinsic discount
GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
Fair Value
·Fair Value CHF 240.45 27.6% undervalued intrinsic discount
Aging Global Demand And Minimally Invasive Procedures Will Reinvent Aesthetics
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Global Controls And Biosimilar Risks Will Squeeze Margins
Galderma’s growth story faces a tougher reality as regulators, cheaper copycat drugs, and shifting skincare tastes threaten the pricing power behind its biggest brands. See why these pressures could squeeze profits even as new product launches and expansion into new markets keep demand looking strong.Read more
AN
CHF 131.68
32.2% overvalued intrinsic discount
Fair Value
Revenue
18.1% p.a.
Profit Margin
16.64%
Future PE
29.03x
Price in 2029
CHF 147.3
GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside
Galderma is leaning into newer skin and beauty treatments that doctors seem excited about, and that could keep demand strong as more people spend on looking and feeling their best. The catch is that sales depend heavily on a handful of recent launches while competition, regulation, and rising spending on marketing and research could squeeze profits if momentum fades.Read more
AN
CHF 188.31
7.6% undervalued intrinsic discount
Fair Value
Revenue
17.59% p.a.
Profit Margin
20.07%
Future PE
34.67x
Price in 2029
CHF 210.66
Aging Global Demand And Minimally Invasive Procedures Will Reinvent Aesthetics
Key Takeaways Nemluvio and Galderma's innovation pipeline could drive much stronger earnings growth and margin expansion than currently anticipated by the market. Execution in premium product segments and underpenetrated markets positions Galderma for significant, sustained gains in global revenue and market share.Read more
AN
CHF 240.45
27.6% undervalued intrinsic discount
Fair Value
Revenue
21.25% p.a.
Profit Margin
21.3%
Future PE
39.18x
Price in 2029
CHF 268.74
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
GALD: FDA Manufacturing Setbacks And Rich P/E Will Likely Cap Future Upside
Fair Value: CHF 131.68 32.2% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GALD: Higher CHF Sentiment Will Test Acne Franchise Concentration Risk
Fair Value: CHF 188.31 7.6% undervalued intrinsic discount
10 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GALD: Higher Fair Value View Will Support Future Re Rating Conviction
Fair Value: CHF 240.45 27.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Galderma Group AG Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Jul 23, 2026
- 2.61
- 68.86%
- 11.70%
- 32.0%
About GALD
- Founded
- 1981
- Employees
- 7676
- CEO
- WebsiteView website
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
